Navigation Links
Orexigen(R) Therapeutics to Speak at Canaccord Adams Global Growth Conference
Date:8/5/2009

SAN DIEGO, Aug. 5 /PRNewswire-FirstCall/ -- Orexigen(R) Therapeutics, Inc. (Nasdaq: OREX), a biopharmaceutical company focused on the treatment of obesity, today announced that the Company will be speaking at the 29th Annual Canaccord Adams Global Growth Conference. The details are as follows:

    Date:  Thursday, August 13, 2009
    Time:  10:00 a.m. Eastern
    Location: InterContinental Boston, London Room
    Speaker: Michael Narachi, Chief Executive Officer

About Orexigen Therapeutics

Orexigen Therapeutics, Inc. is a biopharmaceutical company focused on the development of pharmaceutical product candidates for the treatment of obesity. The Company's lead combination product candidates targeted for obesity are Contrave(R), which completed Phase 3 clinical trials and is on track for a regulatory submission with the FDA in the first half of 2010, and Empatic(TM) which is in the later stages of Phase 2 clinical development. Each product candidate is designed to act on a specific group of neurons in the central nervous system with the goal of achieving appetite suppression and sustained weight loss. Further information about the Company can be found at www.orexigen.com.


'/>"/>
SOURCE Orexigen Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Orexigen(R) Therapeutics Announces Full Exercise of Overallotment Option by Underwriters
2. Orexigen(R) Therapeutics Presents Additional NB-302 Contrave(R) Data at American Diabetes Association (ADA) 69th Scientific Sessions
3. Orexigen(R) Therapeutics Announces Upcoming Data Presentations at American Diabetes Association and Endocrine Society Annual Scientific Meetings
4. Orexigen(R) Therapeutics to Present at Upcoming Meetings
5. Orexigen(R) Therapeutics Announces Jay Hagan as Senior Vice President, Corporate Development and Strategy
6. Orexigen(R) Therapeutics to Speak at Upcoming Conferences
7. Orexigen(R) Therapeutics Announces First Quarter 2009 Financial Results
8. Orexigen(R) Therapeutics Names Michael Scaife Senior Vice President of Regulatory Affairs and Product Development, Contrave(R) Program
9. Orexigen(R) Therapeutics Schedules March 12, 2009 Webcast Discussion of Financial Results for the Fourth Quarter and Year Ended December 31, 2008
10. Orexigen(R) Therapeutics to Speak at BIO CEO & Investor Conference
11. Orexigen(R) Therapeutics Announces First of Four Phase 3 Trials of Contrave(R) Meets Co-Primary and Key Secondary Endpoints
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... VA (PRWEB) January 15, 2014 Two ... have continued their sponsorship of an annual competition for ... in, and access to, innovative STEM study. The competition ... TEAMS: Tests of Engineering Aptitude, Mathematics, and Sciences ...
(Date:1/15/2014)... CA (PRWEB) January 15, 2014 ... research solutions, today announced that Lupin Limited, one of ... Freeslate’s CM Protégé PharmD System for high ... Mumbai, India, is focused on a wide range of ...
(Date:1/14/2014)... 2014 Carahsoft and CDS Federal Services ... 2014 at 2pm EST (11am PST), “Natural Language Processing: ... on how technology can turn raw, heterogeneous data into ... agencies. The online webinar will last approximately one hour. ...
(Date:1/14/2014)... New York, NY (PRWEB) January 14, 2014 ... coverage of Alliqua, Inc. (OTCQB: ALQA). Alliqua is an ... products to serve the wound care market. , Free ... Alliqua was restructured with a seasoned management team and ...
Breaking Biology Technology:Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 2Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 3Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 4Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 5Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 2Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 3Webcast - Natural Language Processing: Converting Raw Data into Actionable Knowledge – Hosted by Carahsoft and CDS Federal Services 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3
... If you're on the Midwest technology job market today, ... You've also learned something about interviewing, thank-you letters and ... ,If youre an older job seeker, though, you may ... to surmount your search: your age. Wait. Isn't age ...
... the weeks since, I've been asked many times why the ... of course, one very practical reason: No compelling new services ... that's the easy out. , ,As I've written before, social ... a clear avenue to revenue that returns value to customers ...
... Wisconsin-based businesses and organizations have formed a unique ... efforts of the Medical College of Wisconsin Research ... commercialization activities. The foundation announced the funding along ... Marketing and Licensing, whose primary purpose will be ...
Cached Biology Technology:How 40-plus tech job seekers can prevent age discrimination 2How 40-plus tech job seekers can prevent age discrimination 3How 40-plus tech job seekers can prevent age discrimination 4Social Networks Revisited 2Social Networks Revisited 3Medical College gets support to expand technology commercialization 2Medical College gets support to expand technology commercialization 3Medical College gets support to expand technology commercialization 4
(Date:4/18/2014)... researchers led by a University of California, Riverside professor ... million Department of Defense grant to uncover fundamental design ... the predictable design of light-weight, tough and strong advanced ... plants and animals, including the mantis shrimp, toucan and ... constructed over millions of years and coming up with ...
(Date:4/17/2014)... of stem cell therapies to cure a variety of ... populations based on cell surface markers. Researchers from the ... is highly expressed in a type of stem cells ... in an article in BioResearch Open Access , ... The article is available free on the ...
(Date:4/17/2014)... births, Down syndrome - or trisomy 21 - is ... results from a chromosomal abnormality where cells of affected ... of the human genome). A study conducted by Stylianos ... Medicine and Development at the University of Geneva (UNIGE) ... light on how the extra chromosome 21 upsets the ...
Breaking Biology News(10 mins):Mantis shrimp, toucan and trilobite, oh my 2Mantis shrimp, toucan and trilobite, oh my 3Trisomy 21: How an extra little chromosome throws the entire genome off balance 2Trisomy 21: How an extra little chromosome throws the entire genome off balance 3
... soldier is wounded during combat, surgeons must focus on ... that could improve the repair and regeneration processes are ... they are not being moved quickly enough into military ... Tech Center for Advanced Bioengineering for Soldier Survivability want ...
... person who dies suddenly should always be referred for ... they too are at risk of sudden death, a ... of Human Genetics today (Tuesday 26 May). ... the Department of Cardiogenetics, Academic Medical Centre, Amsterdam, The ...
... IMMEDIATE RELEASE An advance in solving the mysterious ... Scientists in Ohio are reporting a ... than one million machinists in the United States who ... fluids. Those fluids become airborne during machining of metal ...
Cached Biology News:New center at Georgia Tech aims to improve recovery of soldiers with severe injuries 2New center at Georgia Tech aims to improve recovery of soldiers with severe injuries 3Comprehensive cardiogenetic testing for families of sudden unexplained death victims can save lives 2American Chemical Society's Weekly PressPac -- May 20, 2009 2American Chemical Society's Weekly PressPac -- May 20, 2009 3American Chemical Society's Weekly PressPac -- May 20, 2009 4American Chemical Society's Weekly PressPac -- May 20, 2009 5American Chemical Society's Weekly PressPac -- May 20, 2009 6American Chemical Society's Weekly PressPac -- May 20, 2009 7American Chemical Society's Weekly PressPac -- May 20, 2009 8American Chemical Society's Weekly PressPac -- May 20, 2009 9American Chemical Society's Weekly PressPac -- May 20, 2009 10
Request Info...
...
... Radiochemical Purity is >95%\nNEN Radiolabeled Ligands\n\nReceptor-related research ... availability of new radiolabeled ligands selected to ... a wide range of products and services ... over 400 state-of-the-art radioligands. If you do ...
Request Info...
Biology Products: